Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09

Inclusion criteria

• Healthy subjects
• Male's mass is ≥50 kg, female's mass is ≥45 kg, have a body mass index between 18 and 26 kg/m^2
• Subjects or their legal representative signed informed consent
• agree to use instruments of contraception from the time of the first dose until 6 months after the last dose of investigational drug, avoid pregnancy make yourself or your mate
• Able to keep good communication with investigator and comply with the requirements of the clinical trials

Exclusion criteria

• Smokers,quitting time less than 3 months , or can't quit smoking during the trial
• Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing,or being treated for a direct lower gastrointestinal or using steroids
• Participation in any clinical investigation within 3 months prior to dosing
• Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing
• Significant illness within 2 weeks prior to dosing,and investigator judge doesn't fit to participate in this trial
• A history of clinical significance of abnormal ECG
• A history of diabetes, hyperuricemia and hyperlipidemia
• A history of acute or chronic bronchial spasms
• Have clinical significant gastrointestinal diseases
• Have serious, progressive, or uncontrolled organ or system diseases
• Abuse of drug or alcohol within 12 months before first dosing
• People who are pregnant, nursing mothers, or in the near future plan to be pregnant,or show pregnancy test positive before into group
• Subjects who, in the opinion of the investigator, are in any way unsuitable to participate in the study